rs12700667 — 7p15.2 (near HOXA10/HOXA11)
Intergenic GWAS locus upstream of homeobox genes HOXA10 and HOXA11 that may influence their regulation; carrying the A allele is associated with increased risk of endometriosis, particularly moderate-to-severe disease
Details
- Gene
- 7p15.2 (near HOXA10/HOXA11)
- Chromosome
- 7
- Risk allele
- A
- Consequence
- Regulatory
- Inheritance
- Additive
- Clinical
- Risk Factor
- Evidence
- Established
- Chip coverage
- v3 v4 v5
Population Frequency
Ancestry Frequencies
Related SNPs
Category
Fertility & Reproductive HealthSee your personal result for 7p15.2 (near HOXA10/HOXA11)
Upload your DNA data to find out which genotype you carry and what it means for you.
Upload your DNA dataWorks with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.
The 7p15.2 Locus — A Regulatory Variant Near Genes That Shape the Uterus
Endometriosis — in which tissue resembling the uterine lining grows outside the uterus — affects
an estimated 10% of women of reproductive age and accounts for a significant share of chronic
pelvic pain and infertility. Despite its prevalence, most cases take
4 to 11 years to diagnose11 4 to 11 years to diagnose
Diagnosis requires laparoscopy to confirm; symptoms are often
normalized or attributed to primary dysmenorrhea.
Roughly half of endometriosis susceptibility is heritable. rs12700667 is one of the strongest
and most replicated common genetic risk signals yet discovered for the disease.
The variant sits in an intergenic region on chromosome 7p15.2 — between protein-coding genes —
approximately 331 kilobases upstream of NFE2L3 (a transcription factor implicated in
inflammation and cell differentiation) and roughly 1.35 megabases from the
HOXA10 and HOXA11 homeobox genes22 HOXA10 and HOXA11 homeobox genes
Homeobox genes encode transcription factors that
control body plan patterning; in adults, HOXA10 and HOXA11 continue to regulate endometrial
development and receptivity.
Intergenic variants at this distance can still influence gene expression by altering
long-range chromatin interactions and enhancer activity.
The Mechanism
HOXA10 and HOXA11 are essential transcription factors for the development of the Müllerian
ducts into the uterus and are dynamically regulated by estrogen and progesterone throughout the
menstrual cycle. Their expression peaks during the mid-secretory phase — the implantation
window — where they coordinate endometrial stromal decidualization, immune modulation, and
epithelial receptivity. In women with endometriosis, HOXA10 expression is consistently
reduced in the eutopic endometrium:
this downregulation stems from a combination of epigenetic hypermethylation and chronic
inflammatory signals generated by ectopic implants33 this downregulation stems from a combination of epigenetic hypermethylation and chronic
inflammatory signals generated by ectopic implants
Reduced HOXA10 in the endometrium
impairs decidualization and uterine receptivity, contributing to the infertility associated
with endometriosis.
The rs12700667 locus may act as a regulatory element that influences baseline transcriptional activity of these HOX genes. Carrying the A risk allele could subtly alter enhancer interactions with the HOXA cluster, lowering the threshold for endometrial dysfunction and ectopic implant establishment. Functional studies to confirm this mechanism are ongoing; the locus also contains a microRNA (hsa-mir-148a) and non-coding RNA transcripts that may independently contribute.
The Evidence
The initial discovery came from a
genome-wide association study of 3,194 surgically confirmed endometriosis cases and 7,060
controls from Australia and the UK, subsequently replicated in a US cohort44 genome-wide association study of 3,194 surgically confirmed endometriosis cases and 7,060
controls from Australia and the UK, subsequently replicated in a US cohort
Painter et al.
Nature Genetics, 2011.
The combined dataset of 5,586 cases and 9,331 controls reached genome-wide significance
(P = 1.4 × 10⁻⁹). The odds ratio for any endometriosis was 1.20 (95% CI 1.13–1.27), rising
to 1.38 (95% CI 1.24–1.53, P = 1.5 × 10⁻⁹) for moderate-to-severe disease (Stage III/IV).
A subsequent meta-analysis of eight GWAS datasets55 meta-analysis of eight GWAS datasets
Rahmioglu et al. Human Reproduction Update,
2014 across European and Japanese populations
confirmed the association with consistent directional effect and no significant heterogeneity:
OR 1.13 for all endometriosis (P = 1.6 × 10⁻⁹) and OR 1.22 for stage III/IV enriched
samples (P = 4.2 × 10⁻¹¹). The risk allele A is common in European populations (frequency
approximately 0.74), so most women carry at least one copy — but homozygosity approximately
doubles the additional risk compared to heterozygosity.
The effect is notably stronger for advanced disease. Five of the six replicated endometriosis
loci, including 7p15.2, show larger odds ratios when restricted to Stage III/IV cases.
In Polish women with endometriosis and infertility specifically, the odds ratio for severe
stages reached 1.3966 1.39
Szczepańska et al. Arch Med Sci, 2018.
The variant has replicated in East Asian (Japanese and Chinese) cohorts, demonstrating
cross-ethnic generalizability despite very different A allele frequencies in those populations
(~0.18 in East Asians).
Practical Implications
Carrying the A allele at rs12700667 raises the population-level probability of developing endometriosis. The absolute risk conferred by a single common variant of moderate effect is modest, but the biological pathway implicated — HOX gene regulation and endometrial development — points to concrete clinical surveillance strategies.
The most actionable implication is awareness of early symptoms and willingness to escalate to specialist evaluation. Dysmenorrhea that disrupts daily function, deep dyspareunia, cyclic bowel or bladder symptoms, and chronic pelvic pain are all cardinal presentations. Because endometriosis can only be definitively confirmed by laparoscopy, many cases are managed presumptively based on clinical presentation and ultrasound — a gynecologist with endometriosis expertise can guide the diagnostic pathway without immediately requiring surgery.
For A/A homozygotes, the modestly elevated risk is worth factoring into family planning discussions and fertility workup timing. Endometriosis-associated infertility can be treated with excision surgery, medical suppression, or assisted reproduction, but earlier diagnosis generally allows more options and less disease progression.
Interactions
rs7521902 (near WNT4): WNT4 encodes a signaling protein that suppresses androgen production and supports normal female reproductive development. The rs7521902 locus is one of the most strongly replicated endometriosis GWAS hits (P = 1.8 × 10⁻¹⁵ in large meta-analyses) and has also been linked to PCOS susceptibility through opposing effects on androgen signaling. Carrying risk alleles at both 7p15.2 and WNT4 loci may confer additive endometriosis susceptibility, though formal interaction testing across both variants has not yet been published.
rs1250248 (FN1 — fibronectin 1): An epistatic interaction between rs7521902 (WNT4) and rs1250248 (FN1) has been described specifically for ovarian endometriosis. Fibronectin is a major extracellular matrix protein implicated in cell adhesion and migration; altered fibronectin expression may facilitate ectopic implant attachment and invasion.
For a supervisor compound action proposal: women carrying the risk allele at rs12700667 (AA or AG) who also carry the risk allele at rs7521902 (WNT4 locus) may represent a subgroup with meaningfully higher cumulative endometriosis risk. If both loci show risk alleles, the combined recommendation would be earlier and more aggressive specialist referral for pelvic pain symptoms, and proactive fertility counseling by age 30. Evidence level: moderate (consistent direction across GWAS studies, no formal gene-gene interaction paper).
Genotype Interpretations
What each possible genotype means for this variant:
No copies of the 7p15.2 endometriosis risk allele
You carry two copies of the G allele at rs12700667, meaning you do not carry the A risk allele associated with elevated endometriosis susceptibility at this locus. About 11% of people of European ancestry share this genotype.
This does not eliminate endometriosis risk — the condition is influenced by many genetic and environmental factors — but you do not carry this particular genetic contribution.
Two copies of the endometriosis risk allele — highest genetic susceptibility at this locus
The AA homozygous genotype places you at the higher end of the genetic risk distribution for endometriosis at this locus. The 7p15.2 locus is one of nine genome-wide significant loci identified through large-scale meta-analysis, and rs12700667 remains among the most significant single-marker associations (P = 1.6 × 10⁻⁹ across all endometriosis; P = 4.2 × 10⁻¹¹ for stage III/IV enriched samples).
The candidate mechanism involves long-range regulatory effects on HOXA10 and HOXA11 — homeobox transcription factors whose expression is consistently reduced in the endometrium of women with endometriosis. Reduced HOXA10 expression impairs stromal decidualization, disrupts implantation-window immune tolerance, and may create a permissive environment for retrograde endometrial cells to implant on peritoneal surfaces.
For women who have experienced symptoms and have not yet received a diagnosis: the average diagnostic delay for endometriosis remains 4–11 years from symptom onset. This is driven by normalization of menstrual pain, limited public awareness, and the requirement for laparoscopic confirmation. Knowing this genetic background provides an additional motivation to pursue proactive evaluation rather than waiting.
For women who are asymptomatic: this result is not diagnostic and most AA carriers will not develop clinically significant endometriosis. It is a signal worth factoring into symptom monitoring and fertility planning, not a source of alarm.
For men: you cannot develop endometriosis, but you may pass the A allele to daughters. This result has relevance primarily for offspring counseling.
One copy of the endometriosis risk allele — modestly elevated susceptibility
The risk conferred by heterozygosity at this locus is real but modest on an individual level — population-based genetic risk estimates are useful for awareness rather than deterministic prediction. Endometriosis has a population prevalence of approximately 10% in reproductive-age women; carrying one copy of this risk allele may shift that estimate modestly upward, with the greatest effect on severe, surgically confirmed disease.
The 7p15.2 locus likely acts through long-range regulation of HOXA10 and/or HOXA11, homeobox transcription factors that orchestrate endometrial development and receptivity. Reduced baseline HOX expression in the endometrium is a consistent finding in women with endometriosis and may underlie both the implant-promoting environment and the impaired uterine receptivity that contributes to infertility.
Diagnostic delay averages 4–11 years from symptom onset to confirmed endometriosis. Being aware of this genetic signal and its associated phenotype can help you recognize relevant symptoms earlier and seek appropriate evaluation sooner.
Key References
Discovery GWAS (5,586 cases / 9,331 controls) identifying rs12700667 at 7p15.2 as genome-wide significant for endometriosis (OR 1.20, P = 1.4 × 10⁻⁹); OR 1.38 for moderate-to-severe disease
Meta-analysis of eight GWAS datasets confirming rs12700667 at OR 1.13 (all endometriosis, P = 1.6 × 10⁻⁹) and OR 1.22 for stage III/IV disease
Italian replication and meta-analysis confirming 7p15.2 and additional loci WNT4, CDKN2BAS as endometriosis susceptibility loci
Replication study in Chinese population confirming association of rs12700667 with ovarian endometriosis
Polish cohort study showing significant association of rs12700667 with infertility risk in women with endometriosis, particularly stages III/IV (OR 1.394)
Early study demonstrating altered HOX gene expression in endometrium of women with endometriosis, supporting candidate gene hypothesis